{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:01:07Z","timestamp":1791396067329,"version":"4.3.3"},"reference-count":25,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T00:00:00Z","timestamp":1459728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:p>\n                    Refractory anemia with ring sideroblasts and thrombocytosis (RARS\u2010T) shares overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). RARS\u2010T is characterized by\n                    <jats:italic>SF3B1<\/jats:italic>\n                    and\n                    <jats:italic>JAK2<\/jats:italic>\n                    mutations and prognosis is considered to be better than MDS but not as good as MPN. The objective of the study was to identify predictors of survival in RARS\u2010T. We analyzed clinical and laboratory variables in 82 patients and applied a 27\u2010gene NGS assay to 48 marrow samples obtained at diagnosis. 94% of patients had \u22651 mutations; common mutations being:\n                    <jats:italic>SF3B1<\/jats:italic>\n                    85%,\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F 33%,\n                    <jats:italic>ASXL1<\/jats:italic>\n                    29%,\n                    <jats:italic>DNMT3A<\/jats:italic>\n                    13%,\n                    <jats:italic>SETBP1<\/jats:italic>\n                    13% and\n                    <jats:italic>TET2<\/jats:italic>\n                    10%. In a multivariable survival analysis (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200982), anemia (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.02) [HB&lt; 10 gm\/dl: HR 2.3, 95% CI 1.2\u20134.6] and abnormal karyotype (\n                    <jats:italic>P<\/jats:italic>\n                    =.01) [HR 6.1, 95% CI 2.7\u201013.8] were independently prognostic for inferior survival. In patients with NGS information (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200948), univariate analysis showed association between poor survival and presence of\n                    <jats:italic>SETBP1<\/jats:italic>\n                    (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.04) or\n                    <jats:italic>ASXL1<\/jats:italic>\n                    (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.08) mutations whereas the absence of these mutations (\n                    <jats:italic>ASXL1<\/jats:italic>\n                    wt\/\n                    <jats:italic>SETBP1<\/jats:italic>\n                    wt) was favorable (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.04); the number of concurrent mutations did not provide additional prognostication (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.3). We developed a HR\u2010weighted prognostic model, with 2 points for an abnormal karyotype, 1 point for either\n                    <jats:italic>ASXL1<\/jats:italic>\n                    and\/or\n                    <jats:italic>SETBP1<\/jats:italic>\n                    mutations, and 1 point for a HB level\u2009&lt;\u200910 gm\/dl, which effectively stratified patients into three risk categories; low (0 points), intermediate (1 point) and high (\u22652 points), with median survivals of 80, 42 and 11 months respectively (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.01). In summary, we confirm the unique mutational landscape in RARS\u2010T and provide a novel mutation\u2010enhanced prognostic model. Am. J. Hematol. 91:492\u2013498, 2016. \u00a9 2016 Wiley Periodicals, Inc.\n                  <\/jats:p>","DOI":"10.1002\/ajh.24332","type":"journal-article","created":{"date-parts":[[2016,2,14]],"date-time":"2016-02-14T01:36:17Z","timestamp":1455413777000},"page":"492-498","source":"Crossref","is-referenced-by-count":77,"title":["Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS\u2010T) and the role of next\u2010generation sequencing"],"prefix":"10.1002","volume":"91","author":[{"given":"Mrinal M.","family":"Patnaik","sequence":"first","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra L.","family":"Lasho","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy M.","family":"Finke","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Department of Laboratory Medicine Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"King","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Department of Laboratory Medicine Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett P.","family":"Ketterling","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,4,4]]},"reference":[{"key":"e_1_2_6_2_1","volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S","year":"2008"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24038"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.119032"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.053918"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377994"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.49"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311347"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312542"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.120"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.88"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.125"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310523"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23373"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-415356"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.122"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214514"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2696"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2495"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.113"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.97"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.58"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.06.032"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8307"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.3314"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-518886"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24332","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24332","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T20:23:03Z","timestamp":1695500583000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,4]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1002\/ajh.24332"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24332","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,4]]}}}